clinical trial · NCT04185883
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
Amgen·phase1·active not recruiting·n = 610
Advanced Solid TumorsKirsten Rat Sarcoma (KRAS) pG12C MutationSotorasibTrametinibRMC-4630AfatinibPembrolizumabPanitumumabCarboplatin, pemetrexed, docetaxel, paclitaxelAtezolizumab
brief summary
To evaluate the safety and tolerability of sotorasib administered in investigational regimens in adult participants with KRAS p.G12C mutant advanced solid tumors.
started
Dec 17, 2019
primary completion
Dec 17, 2026
completion
Dec 5, 2027
last updated
Oct 22, 2025
official title
A Phase 1b, Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Sotorasib Monotherapy and in Combination With Other Anti-cancer Therapies in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol